REG - Oakley Capital Inv. - Oakley Capital invests in ProductLife Group

Oakley Capital InvestmentsAnnouncement

28/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240528:nRSb9326Pa&default-theme=true

RNS Number : 9326P  Oakley Capital Investments Limited  28 May 2024

28 May 2024

Oakley Capital Investments Limited

 

Oakley Capital Investments Limited(1) ("OCI") is pleased to announce that
Oakley Capital Fund V(2) ("Fund V") has agreed to invest in ProductLife Group,
a European provider of outsourced regulatory and compliance services to the
global life sciences industry.

OCI's indirect contribution via Fund V is anticipated to be c.£41 million,
which relates to OCI's share of Oakley's investment in ProductLife Group.

Further details on the transaction can be found in the below announcement from
Oakley Capital(3.)

( )

Oakley Capital invests in ProductLife Group, a leading player in regulatory
and compliance services to the global life sciences industry

 

Oakley Capital, a leading pan-European private equity investor, is pleased to
announce that Oakley Capital Fund V is investing in ProductLife Group, a
European provider of outsourced development, regulatory and compliance
services to the global life sciences industry.

ProductLife Group provides development, regulatory affairs, market access,
pharmacovigilance, quality management and digital transformation services
mainly to clients in the pharmaceuticals industry. The business has a
diversified customer base with over 1,000 clients including 75% of the 50
largest global pharma companies. Under the leadership of Xavier Duburcq,
ProductLife Group has grown significantly over the last four years, completing
16 add-on acquisitions and generating double-digit organic revenue growth.
Today, ProductLife Group employs more than 1,600 people and operates across
150+ countries globally.

Oakley will work alongside management and the reinvesting shareholder, 21
Invest, leveraging our buy-and-build track record, supporting the business'
continued international expansion and accelerating investments into AI
technology to drive technology enablement of its services and operations.

Oakley Capital founder and Managing Partner Peter Dubens said:

"We're pleased to be investing in ProductLife Group. This is an attractive
business in a large, non-cyclical market where increased regulation and
outsourcing are driving growth. At the same time, the Group's investments in
technology enablement are expected to drive competitive advantages in the
coming years. We look forward to working with Xavier and his management team
to take full advantage of this potential."

ProductLife Group CEO Dr. Xavier Duburcq said:

"We see tremendous opportunity to expand our business in the fragmented pharma
services market both organically but also through acquisitions. Oakley has
significant expertise executing buy-and-build and internationalisation
strategies and we welcome the opportunity to collaborate with them on the next
stage of ProductLife Group's journey."

 

- ends -

 

For further information please contact:

 

Oakley Capital Limited

+44 20 7766 6900

Steven Tredget

 

Greenbrook Communications Limited

+44 20 7952 2000

Rob White / Michael Russell

 

Deutsche Numis (Financial Adviser & Broker)

+44 20 7260 1000

Nathan Brown / Matt Goss

 

Notes:

LEI Number: 213800KW6MZUK12CQ815

(1 )About Oakley Capital Investments Limited ("OCI")

OCI is a Specialist Fund Segment ("SFS") traded investment vehicle that aims
to provide shareholders with consistent long-term capital growth in excess of
the FTSE All-Share Index by providing liquid access to private equity returns
through investment in the Oakley Funds.

A video introduction to OCI is available
at https://oakleycapitalinvestments.com/videos/
(https://oakleycapitalinvestments.com/videos/)

The contents of the OCI website are not incorporated into, and do not form
part of, this announcement.

(2) The Oakley Funds

Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley
Capital IV, Oakley Capital V, Oakley Capital Origin and Oakley Capital Origin
II are unlisted lower-mid to mid-market private equity funds that aim to
provide investors with significant long-term capital appreciation. The
investment strategy of the Funds is to focus on buy-out opportunities in
industries with the potential for growth, consolidation and performance
improvement. The Oakley family of funds also includes Oakley PROfounders Fund
III and Oakley Touring Venture Fund, which are venture capital funds focused
on investments in entrepreneur-led, disruptive, technology led companies.

(3) Oakley Capital, the Investment Adviser

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability
to source attractive growth assets at attractive prices. To do this it relies
on its sector and regional expertise, its ability to tackle transaction
complexity and its deal generating entrepreneur network.

Important information

Specialist Fund Segment securities are not admitted to the Official List of
the Financial Conduct Authority. Therefore, the Company has not been required
to satisfy the eligibility criteria for admission to listing on the Official
List and is not required to comply with the Financial Conduct Authority's
Listing Rules.

The Specialist Fund Segment is intended for institutional, professional,
professionally advised and knowledgeable investors who understand, or who have
been advised of, the potential risk from investing in companies admitted to
the Specialist Fund Segment.

This announcement may include "forward-looking statements". These
forward-looking statements are statements regarding the Company's objectives,
intentions, beliefs or current expectations with respect to, amongst other
things, the Company's financial position, business strategy, results of
operations, liquidity, prospects and growth. Forward-looking statements are
subject to risks and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future.  Accordingly the
Company's actual future financial results, operational performance and
achievements may differ materially from those expressed in, or implied by, the
statements. Given these uncertainties, prospective investors are cautioned not
to place any undue reliance on such forward-looking statements, which speak
only as at the date of this announcement. The Company expressly disclaims any
obligation or undertaking to update or revise any forward-looking statements
contained herein to reflect actual results or any change in the Company's
expectations with regard to them or any change in events, conditions or
circumstances on which any such statements are based unless required to do so
by the Financial Services and Markets Act 2000, the Listing Rules or
Prospectus Regulation Rules of the Financial Conduct Authority or other
applicable laws, regulations or rules.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQQKABDKBKBPPB